NATURE’S SUNSHINE PRODUCTS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $300.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-08.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2019-03-08
- NATURE’S SUNSHINE PRODUCTS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2016 was $300.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|
| 2016-12-31 | $300.00K 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |